Obermatt
See Similar Stocks →

Jeil Pharma

KSC:002620 · KR7002620003
PharmaceuticalsSmall

360

73
Medium confidence — indicative
Profit price34
Owner Earnings Yield84
Dividend Yield1
Price/Sales95
EV / Gross Profit91
Price/Book93
Return on Capital84
Cash Return on Capital74
Return on Equity80
EBIT Margin72
Gross Profitability60
Cash Conversion43
Accruals36
Owner Earnings Margin72
Sales growth5
Profit Growth33
Long-Term EPS Growth85
Reinvestment30
Price momentum61
Debt load58
Refinancing94
Debt Payback28
Liquidity50
Analyst ratings—
Expectations trend—
Market mood1
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Jeil Pharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
ISINKR7002620003
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
RheumatologyUrologyCardiovascularNeurologyOncologyEndocrinologyBiotechnologyManufacturing

Description

Analysis

Middle-of-the-road

Jeil Pharma Holdings Inc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 5.3×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Jeil Pharma with its peers
Jeil Pharmaceutical
KSC:271980
70
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hanall Biopharma
KSC:009420
30
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
JW
KSC:096760
97
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Boryung
KSC:003850
94
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
JW Pharmaceutical
KSC:001060
95
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Eisai
TYO:4523
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →